VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).
暂无分享,去创建一个
J. Blay | M. Hidalgo | J. Baselga | J. Tabernero | D. Hyman | E. Chan | J. Wolf | N. Raje | I. Chau | F. Sirzén | M. L. Veronese | L. Mitchell | F. Sirzén | E. Chan